First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

(2021) Nicoletta Colombo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study

(2019) Hyun Cheol Chung et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial

(2017) Jean-Sebastien Frenel et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

(2017) Krishnansu S Tewari et al.   LANCET

Improved Survival with Bevacizumab in Advanced Cervical Cancer

(2014) Krishnansu S. Tewari et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study

(2009) Bradley J. Monk et al.   JOURNAL OF CLINICAL ONCOLOGY